carmustine has been researched along with Lymphoma in 169 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018." | 9.30 | Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019) |
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 9.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| "We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)." | 9.11 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004) |
| "To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting." | 9.10 | High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003) |
| "We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for patients with advanced relapsed or refractory indolent lymphoma." | 9.09 | Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. ( Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J, 2000) |
| " Thirty seven patients with refractory lymphoma received 400 mg/m2/day of etoposide, and 13 patients 600 mg/m2/day, in addition to BCNU, cytarabine, and melphalan." | 9.08 | Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. ( Goldstone, AH; Linch, DC; Mills, W; Strang, J, 1995) |
| "Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT." | 9.07 | High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 9.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 9.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse." | 7.83 | Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016) |
| "Single-dose palonosetron was more effective than ondansetron treatment to prevent acute and delayed nausea and vomiting following HDC before HSCT." | 7.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m2 i." | 7.70 | Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 7.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 7.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy." | 7.67 | Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 7.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "SUMMARY-A model has been derived for the effect of the chemotherapeutic agents cyclophosphamide (CY), 5-fluorouracil (5-FU), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on the survival of mice bearing a transplantable lymphoma." | 7.64 | Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bruce, WR; Meeker, BE; Valeriote, FA, 1967) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 6.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods." | 5.72 | Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022) |
| " We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT." | 5.42 | High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015) |
| "A total of 123 patients with lymphoma receiving the BEAM (carmustine, etoposide, aracytin, and melphalan) conditioning regimen had a significant 5% drop in mean forced vital capacity and total lung capacity but no significant change in forced expiratory volume in one second/forced vital capacity ratio nor in diffusion lung capacity of carbon monoxide adjusted to volume." | 5.34 | Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. ( Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A, 2020) |
| " In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018." | 5.30 | Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. ( Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J, 2019) |
| "Bacteremia was documented in two patients in the O+R group and six in the control group (p=0." | 5.30 | Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999) |
| "Twenty-four patients autografted for malignant lymphoma have been followed." | 5.29 | Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas. ( Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B, 1993) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 5.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "Levamisole (LMS) has been considered an immunorestorative agent capable of enhancing host's antitumor immune responses." | 5.28 | Role of levamisole as immunomodulant in mouse lymphoma model. ( Bulgarini, B; De Vecchis, L; Giuliani, A; Turriziani, M, 1991) |
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 5.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| "With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation." | 5.15 | A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011) |
| "We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n = 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m(2) (eBEAM; n = 64 from May 1995 to June 1999)." | 5.11 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study. ( Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA, 2004) |
| "To assess the effect of a reduced dose of radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) regimen." | 5.10 | Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. ( Bessell, EM; Byrne, P; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B; Petit, J; Verger, E; Villá, S, 2002) |
| "To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients with non-AIDS-related primary CNS lymphoma (PCNSL) treated in a multicenter setting." | 5.10 | High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. ( Fickers, M; Haaxma-Reiche, H; Hansen, M; Kluin-Nelemans, HC; Poortmans, PM; Rozewicz, C; Soubeyran, P; Taphoorn, M; Teodorovic, I; Thomas, J; Van den Bent, M; van Glabbeke, M; Van Imhoff, G; Van't Veer, M, 2003) |
| "We performed a phase II study to determine the efficacy of maximal cytoreductive therapy with up to five cycles of Dexa-BEAM (dexamethasone, carmustine [BCNU], etoposide, cytarabine, and melphalan) followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for patients with advanced relapsed or refractory indolent lymphoma." | 5.09 | Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma. ( Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J, 2000) |
| " Thirty seven patients with refractory lymphoma received 400 mg/m2/day of etoposide, and 13 patients 600 mg/m2/day, in addition to BCNU, cytarabine, and melphalan." | 5.08 | Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. ( Goldstone, AH; Linch, DC; Mills, W; Strang, J, 1995) |
| "We conducted a dose-finding study of mitoxantrone (MITO) in combination with high-dose cyclophosphamide, carmustine (BCNU), and etoposide (CBV) in refractory lymphoma undergoing autologous bone marrow transplantation (ABMT)." | 5.07 | Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. ( Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D, 1994) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 5.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT." | 5.07 | High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992) |
| "A total of 296 evaluable patients with unfavorable categories of malignant lymphoma were randomly assigned treatment with cyclophosphamide, vincristine, and prednisone plus BCNU (BCOP) or doxorubicin (CHOP)." | 5.05 | Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. ( Bartolucci, AA; Dandy, M; Gams, RA; Omura, G; Rainey, M; Silberman, H, 1985) |
| "Fifty-two patients with stage III or IV nodular mixed lymphocytic-histiocytic lymphoma (NM) were entered on a prospective randomized trial comparing cyclophosphamide-prednisone (CP) to either COPP (cyclophosphamide, vincristine, procarbazine, prednisone) or BCVP (BCNU, cyclophosphamide, vincristine, prednisone)." | 5.05 | Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. ( Barnes, JM; Bennett, JM; Berard, CW; Ezdinli, EZ; Glick, JH; Orlow, EL, 1981) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "Based on experience with comprehensive patient involvement, we present data from implementation of portable, programmable infusion pumps (PPP) for home-based chemotherapy administration in patients with acute leukaemia and in lymphoma patients receiving (carmustine, etoposide, cytarabine, melphalan) BEAM regimen." | 3.88 | Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma. ( Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC, 2018) |
| "Autologous stem cell transplantation (ASCT) following BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low- and high-grade B-cell lymphoma (DLBCL) and other lymphoproliferative disorders, but BCNU is associated with interstitial pneumonia and an increased mortality." | 3.88 | High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity. ( Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R, 2018) |
| "BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas." | 3.88 | A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. ( Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F, 2018) |
| "Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse." | 3.83 | Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. ( Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E, 2016) |
| "High-dose BEAM chemotherapy (BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma." | 3.83 | Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. ( Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| "Single-dose palonosetron was more effective than ondansetron treatment to prevent acute and delayed nausea and vomiting following HDC before HSCT." | 3.75 | Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. ( Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P, 2009) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| "Between January 1996 and July 2002, 72 patients with non-Hodgkin's lymphoma or Hodgkin's disease underwent high-dose chemotherapy with autologous stem cell transplant conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or carmustine, etoposide, cytarabine, melphalan (BEAM) at a single institution." | 3.72 | High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. ( Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH, 2004) |
| "Thirty adults with primary refractory or recurrent intermediate- or low-grade lymphoma were treated on a prospective phase II study with carmustine 300 mg/m2 i." | 3.70 | Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. ( Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K, 1999) |
| " In an attempt to reduce the high procedure-related mortality reported with allografting in lymphoma, we have used BEAM (BCNU, etoposide, cytarabine and melphalan), a standard conditioning regimen for autologous transplantation." | 3.70 | Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. ( Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H, 2000) |
| "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma." | 3.69 | A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. ( Smith, RJ; Sweetenham, JW, 1995) |
| "The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma." | 3.68 | Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. ( Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M, 1993) |
| "One hundred forty-three patients with cutaneous T cell lymphoma were treated with topical carmustine (BCNU)." | 3.68 | Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. ( Crain, WR; Epstein, EH; Zackheim, HS, 1990) |
| "Sixteen children with non-Hodgkin's lymphoma (NHL) who had relapsed were treated with high-dose chemotherapy with BCNU, cyclophosphamide, cytarabine, 6-thioguanine (high-dose chemotherapy [HDC]) and autologous bone marrow transplantation (ABMT)." | 3.67 | High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. ( Beaujean, F; Hartmann, O; Kalifa, C; Lemerle, J; Parmentier, C; Patte, C; Pein, F, 1984) |
| "58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens-(cyclophosphamide, vincristine and prednisone (COP), and BCNU , cyclophosphamide, vincristine, melphalan and prednisone (M-2) - to compare remission induction and duration as well as survival." | 3.67 | Comparison of M-2 protocol with COP in patients with nodular lymphoma. ( Case, DC, 1984) |
| "From 1981 to 1983, 208 patients with recurrent or refractory lymphoma were treated with methylglyoxal-bis-guanylhydrazone (methyl-GAG), ifosfamide, methotrexate, etoposide (MIME)." | 3.67 | Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; Jagannath, S; McLaughlin, P; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS, 1988) |
| "Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy." | 3.67 | Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 3.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "SUMMARY-A model has been derived for the effect of the chemotherapeutic agents cyclophosphamide (CY), 5-fluorouracil (5-FU), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on the survival of mice bearing a transplantable lymphoma." | 3.64 | Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Bruce, WR; Meeker, BE; Valeriote, FA, 1967) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | 2.82 | Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Forty-five malignant lymphoma patients (mean age 38 years, M:F 30:15), undergoing the highly emetogenic regimen BEAM prior to ASCT, were randomized to receive IV granisetron (G) 3 mg once a day, IV tropisetron (T) 5 mg once a day, or IV ondansetron (0) 8 mg twice daily, for six days." | 2.69 | Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. ( Klener, P; Procházka, B; Slabý, J; Trnený, M, 2000) |
| " In summary, the DexaBEAM/G-CSF/CBV strategy appears to be safe and effective for salvage treatment in patients with poor risk malignant lymphomas." | 2.68 | Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. ( Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E, 1996) |
| "Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7." | 2.68 | High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995) |
| "Radiation therapy for five primary brain tumors is discussed based on the results of prospective trials." | 2.42 | [Evidence-based radiation therapy for primary brain tumors]. ( Kono, T; Nankoh, S; Shibamoto, Y; Taniguchi, H; Tomita, N; Tsuji, H, 2003) |
| "Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment methods." | 1.72 | Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma. ( Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I, 2022) |
| " We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT." | 1.42 | High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015) |
| "Pneumonitis is a complication of high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) regimens containing BCNU." | 1.38 | Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. ( Abramson, JS; Armand, P; Brown, JR; Chen, YB; Feng, Y; Fisher, DC; Freedman, AS; Jacobsen, ED; LaCasce, AS; Lane, AA; McAfee, SL; Neuberg, DS; Spitzer, TR, 2012) |
| "In heavily pretreated lymphoma patients in whom poor PBPC mobilization is expected, BMT may represent an attractive option." | 1.33 | Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma. ( Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L, 2005) |
| "Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome." | 1.32 | Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. ( Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL, 2003) |
| "Bacteremia was documented in two patients in the O+R group and six in the control group (p=0." | 1.30 | Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. ( Brunet, S; Martino, R; Muñoz, L; Sierra, J; Subirà, M; Sureda, A, 1999) |
| "Eighteen patients with malignant lymphoma, 10 non-Hodgkin's and 8 Hodgkin's, were treated with high-dose CVB (cyclophosphamide 4 x 1." | 1.29 | High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas. ( Caronia, F; Gentile, S; Indovina, A; Liberti, G; Majolino, I; Patti, C; Pisa, R; Santoro, A; Scimè, R; Vasta, S, 1993) |
| "Twenty-four patients autografted for malignant lymphoma have been followed." | 1.29 | Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas. ( Carlson, K; Hagberg, H; Oberg, G; Simonsson, B; Smedmyr, B, 1993) |
| "Levamisole (LMS) has been considered an immunorestorative agent capable of enhancing host's antitumor immune responses." | 1.28 | Role of levamisole as immunomodulant in mouse lymphoma model. ( Bulgarini, B; De Vecchis, L; Giuliani, A; Turriziani, M, 1991) |
| "The glutathione inhibitor drugs, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and buthionine sulfoximine (BSO), were tested in vitro in order to assess their cytotoxic effectiveness when combined with an enzyme immunotoxin (eIT) composed of a T-cell reactive monoclonal antibody (mAb) 097 coupled to the reactive oxygen-generating enzyme, glucose oxidase (GO) (EC 1." | 1.28 | Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin. ( Beaujean, F; Goavec, M; Ito, H; Morizet, J; Rousseau, V; Stanislawski, M, 1990) |
| " Estrogen replacement should be initiated after transplantation in women to prevent adverse effects of long-term ovarian failure." | 1.28 | Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. ( Bauer, H; Fehrentz, D; Hunstein, W; Keilholz, U; Körbling, M, 1989) |
| " bolus pharmacokinetic data." | 1.28 | Pharmacokinetics of very high-dose oral melphalan in cancer patients. ( Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE, 1990) |
| "Twenty-one patients had malignant lymphomas, three, acute lymphoblastic leukemia (ALL), and two, malignant thymomas." | 1.27 | Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. ( Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ, 1988) |
| "In 11 patients with non-Hodgkin's lymphoma (NHL) there were 2 complete remissions (CRs) and 2 partial remissions (PRs), and in 6 patients with Hodgkin's disease there were 5 CRs." | 1.27 | Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. ( Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL, 1986) |
| "Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy." | 1.26 | Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). ( Bartolucci, AA; Durant, JR; Langford, KH; Murad, TM; Norgard, MJ, 1979) |
| " The three drugs show similar threshold-type dose-response survival curves on asynchronous cells treated for 1 hr." | 1.26 | A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells. ( Drewinko, B; Gottlieb, JA; Loo, TL, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 70 (41.42) | 18.7374 |
| 1990's | 41 (24.26) | 18.2507 |
| 2000's | 24 (14.20) | 29.6817 |
| 2010's | 23 (13.61) | 24.3611 |
| 2020's | 11 (6.51) | 2.80 |
| Authors | Studies |
|---|---|
| Schenone, L | 1 |
| Houillier, C | 1 |
| Tanguy, ML | 1 |
| Choquet, S | 2 |
| Agbetiafa, K | 1 |
| Ghesquières, H | 1 |
| Damaj, G | 2 |
| Schmitt, A | 1 |
| Bouabdallah, K | 1 |
| Ahle, G | 1 |
| Gressin, R | 1 |
| Cornillon, J | 1 |
| Houot, R | 1 |
| Marolleau, JP | 1 |
| Fornecker, LM | 1 |
| Chinot, O | 1 |
| Peyrade, F | 2 |
| Bouabdallah, R | 2 |
| Moluçon-Chabrot, C | 1 |
| Gyan, E | 1 |
| Chauchet, A | 1 |
| Casasnovas, O | 1 |
| Oberic, L | 1 |
| Delwail, V | 2 |
| Abraham, J | 1 |
| Roland, V | 1 |
| Waultier-Rascalou, A | 1 |
| Willems, L | 1 |
| Morschhauser, F | 1 |
| Fabbro, M | 1 |
| Ursu, R | 1 |
| Thieblemont, C | 1 |
| Jardin, F | 1 |
| Tempescul, A | 1 |
| Malaise, D | 1 |
| Touitou, V | 1 |
| Nichelli, L | 1 |
| Le Garff-Tavernier, M | 1 |
| Plessier, A | 1 |
| Bourget, P | 1 |
| Bonmati, C | 1 |
| Wantz-Mézières, S | 1 |
| Giordan, Q | 1 |
| Dorvaux, V | 1 |
| Charron, C | 1 |
| Jabeur, W | 1 |
| Hoang-Xuan, K | 1 |
| Taillandier, L | 1 |
| Soussain, C | 1 |
| Lachance, S | 1 |
| Bourguignon, A | 1 |
| Boisjoly, JA | 1 |
| Bouchard, P | 1 |
| Ahmad, I | 1 |
| Bambace, N | 1 |
| Bernard, L | 1 |
| Cohen, S | 1 |
| Delisle, JS | 1 |
| Fleury, I | 1 |
| Kiss, T | 1 |
| Mollica, L | 1 |
| Roy, DC | 1 |
| Sauvageau, G | 1 |
| Veilleux, O | 1 |
| Zehr, J | 1 |
| Chagnon, M | 1 |
| Roy, J | 1 |
| Cohen, YI | 1 |
| Lebel, E | 1 |
| Zimran, E | 1 |
| Shaulov, A | 1 |
| Stepensky, P | 1 |
| Grisariu, S | 1 |
| Avni, B | 1 |
| Ahern, K | 1 |
| Pham, J | 1 |
| Sanderson, R | 1 |
| Correia De Farias, M | 1 |
| Walsh, K | 1 |
| Bou Akl, I | 1 |
| Matar, M | 1 |
| Khalil, PB | 1 |
| Massoud, R | 1 |
| Ghaoui, N | 1 |
| Karout, L | 1 |
| Zahreddine, A | 1 |
| Bazarbachi, A | 1 |
| El-Cheikh, J | 1 |
| Choi, JY | 1 |
| Kang, HJ | 1 |
| An, HY | 1 |
| Hong, KT | 1 |
| Shin, HY | 1 |
| Marchesi, F | 1 |
| Capria, S | 1 |
| Pedata, M | 1 |
| Terrenato, I | 1 |
| Ballotta, L | 1 |
| Riccardi, C | 2 |
| Papa, E | 1 |
| Riemma, C | 1 |
| Trisolini, S | 1 |
| Celentano, M | 1 |
| Regazzo, G | 1 |
| Ferrara, F | 2 |
| Mengarelli, A | 1 |
| Picardi, A | 1 |
| Kelsey, P | 1 |
| Pearce, R | 1 |
| Perry, J | 1 |
| Kirkland, K | 1 |
| Paul, R | 1 |
| Lambert, J | 2 |
| Peniket, A | 2 |
| Malladi, R | 1 |
| Snowden, JA | 1 |
| Morley, N | 1 |
| AlJohani, NI | 1 |
| Nasani, M | 1 |
| Ahmed, HE | 1 |
| Ur Rehman, J | 1 |
| Nawaz, A | 1 |
| Alzahrani, Z | 1 |
| Albeirouti, B | 1 |
| Gunes, AK | 1 |
| Serin, I | 1 |
| Demir, I | 1 |
| Sarifakiogullari, S | 1 |
| Durusoy, SS | 1 |
| Akkurt, DM | 1 |
| Ince, I | 1 |
| Ozkan, G | 1 |
| Cinli, TA | 1 |
| Pehlivan, M | 1 |
| Kürzel, S | 1 |
| Blaudszun, AR | 1 |
| Stahl, L | 1 |
| Herbst, R | 1 |
| Kroschinsky, F | 2 |
| Birkmann, J | 2 |
| Hänel, A | 1 |
| Schaefer-Eckart, K | 1 |
| Ehninger, G | 2 |
| Fiedler, F | 1 |
| Bornhäuser, M | 2 |
| Fricke, S | 1 |
| Hänel, M | 2 |
| Fridthjof, KS | 1 |
| Kampmann, P | 1 |
| Dünweber, A | 1 |
| Gørløv, JS | 1 |
| Nexø, C | 1 |
| Friis, LS | 1 |
| Nørskov, KH | 1 |
| Welinder, PC | 1 |
| Moser, C | 1 |
| Kjeldsen, L | 1 |
| Møller, T | 1 |
| Noesslinger, T | 1 |
| Panny, M | 1 |
| Simanek, R | 1 |
| Moestl, M | 1 |
| Boehm, A | 1 |
| Menschel, E | 1 |
| Koller, E | 1 |
| Keil, F | 1 |
| Olivieri, J | 1 |
| Mosna, F | 1 |
| Pelosini, M | 1 |
| Fama, A | 1 |
| Rattotti, S | 1 |
| Giannoccaro, M | 1 |
| Carli, G | 1 |
| Tisi, MC | 1 |
| Ferrero, S | 1 |
| Sgherza, N | 1 |
| Mazzone, AM | 1 |
| Marino, D | 1 |
| Calimeri, T | 1 |
| Loseto, G | 1 |
| Saraceni, F | 1 |
| Tomei, G | 1 |
| Sica, S | 1 |
| Perali, G | 1 |
| Codeluppi, K | 1 |
| Billio, A | 1 |
| Olivieri, A | 2 |
| Orciuolo, E | 1 |
| Matera, R | 1 |
| Stefani, PM | 1 |
| Borghero, C | 1 |
| Ghione, P | 1 |
| Cascavilla, N | 1 |
| Lanza, F | 1 |
| Chiusolo, P | 1 |
| Finotto, S | 1 |
| Federici, I | 1 |
| Gherlinzoni, F | 1 |
| Centurioni, R | 1 |
| Fanin, R | 1 |
| Zaja, F | 1 |
| Salhotra, A | 1 |
| Mei, M | 1 |
| Stiller, T | 1 |
| Mokhtari, S | 1 |
| Herrera, AF | 1 |
| Chen, R | 1 |
| Popplewell, L | 1 |
| Zain, J | 1 |
| Ali, H | 1 |
| Sandhu, K | 1 |
| Budde, E | 1 |
| Nademanee, A | 1 |
| Forman, SJ | 1 |
| Nakamura, R | 1 |
| Dos Santos, KB | 1 |
| Costa, LJM | 1 |
| Bettarello, G | 1 |
| da Matta Abreu, M | 1 |
| Mayrink, GTC | 1 |
| Mota, MA | 1 |
| Ribeiro, LC | 1 |
| Pereira, J | 1 |
| Hallack Neto, AE | 1 |
| Scortechini, I | 1 |
| Montanari, M | 1 |
| Mancini, G | 1 |
| Inglese, E | 1 |
| Calandrelli, M | 1 |
| Chiarucci, M | 1 |
| Offidani, M | 1 |
| Capelli, D | 1 |
| Gini, G | 1 |
| Poloni, A | 1 |
| Mancini, S | 1 |
| Raggetti, G | 1 |
| Leoni, P | 1 |
| Marzolini, MA | 1 |
| Thomson, KJ | 1 |
| Dorman, J | 1 |
| D'Sa, S | 1 |
| Martin, N | 1 |
| Borchiellini, D | 1 |
| Coso, D | 1 |
| Gastaud, L | 1 |
| Boscagli, A | 1 |
| Saudes, L | 1 |
| Re, D | 1 |
| Gutnecht, J | 1 |
| Garnier, G | 1 |
| Petit, E | 1 |
| Barriere, J | 1 |
| Naman, H | 1 |
| Rossignol, B | 1 |
| Thyss, A | 1 |
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
| Sellner, L | 1 |
| Boumendil, A | 1 |
| Finel, H | 1 |
| de Rosa, G | 1 |
| Falzetti, F | 1 |
| Scime, R | 2 |
| Kobbe, G | 1 |
| Delmer, A | 1 |
| Sayer, H | 1 |
| Amorim, S | 1 |
| Finke, J | 3 |
| Salles, G | 1 |
| Yakoub-Agha, I | 1 |
| Faber, E | 1 |
| Nicolas-Virelizier, E | 1 |
| Facchini, L | 1 |
| Vallisa, D | 1 |
| Zuffa, E | 1 |
| Sureda, A | 4 |
| Dreger, P | 2 |
| Lasica, M | 1 |
| Taylor, E | 1 |
| Bhattacharyya, P | 1 |
| Bennett, A | 1 |
| Cooke, RE | 1 |
| Stern, C | 1 |
| Agresta, F | 1 |
| Ayton, R | 1 |
| Grigg, A | 1 |
| Flowers, CR | 1 |
| Costa, LJ | 1 |
| Pasquini, MC | 1 |
| Le-Rademacher, J | 1 |
| Lill, M | 1 |
| Shore, TB | 1 |
| Vaughan, W | 1 |
| Craig, M | 1 |
| Freytes, CO | 2 |
| Shea, TC | 1 |
| Horwitz, ME | 1 |
| Fay, JW | 1 |
| Mineishi, S | 1 |
| Rondelli, D | 1 |
| Mason, J | 1 |
| Braunschweig, I | 2 |
| Ai, W | 1 |
| Yeh, RF | 1 |
| Rodriguez, TE | 1 |
| Flinn, I | 1 |
| Comeau, T | 1 |
| Yeager, AM | 1 |
| Pulsipher, MA | 1 |
| Bence-Bruckler, I | 1 |
| Laneuville, P | 1 |
| Bierman, P | 1 |
| Chen, AI | 1 |
| Kato, K | 1 |
| Wang, Y | 1 |
| Xu, C | 1 |
| Smith, AJ | 1 |
| Waller, EK | 1 |
| Kothari, J | 1 |
| Foley, M | 1 |
| Peggs, KS | 1 |
| Mackenzie, S | 1 |
| Thomson, K | 1 |
| Morris, E | 1 |
| Ardeshna, KM | 1 |
| Virchis, AE | 1 |
| Linch, DC | 4 |
| Cashen, AF | 1 |
| Fletcher, T | 1 |
| Ceriotti, C | 1 |
| Gao, F | 1 |
| Ghobadi, A | 1 |
| Vij, R | 1 |
| Stockerl-Goldstein, K | 1 |
| DiPersio, J | 1 |
| Abboud, C | 1 |
| Reid, RM | 1 |
| Baran, A | 1 |
| Friedberg, JW | 3 |
| Phillips, GL | 4 |
| Liesveld, JL | 3 |
| Becker, MW | 2 |
| Wedow, L | 1 |
| Barr, PM | 1 |
| Milner, LA | 2 |
| Gilli, S | 1 |
| Novak, U | 1 |
| Taleghani, BM | 1 |
| Baerlocher, GM | 1 |
| Leibundgut, K | 1 |
| Banz, Y | 1 |
| Zander, T | 1 |
| Betticher, D | 1 |
| Egger, T | 1 |
| Rauch, D | 1 |
| Pabst, T | 1 |
| Fair, C | 1 |
| Shanley, R | 1 |
| Rogosheske, J | 1 |
| Lazaryan, A | 1 |
| McClune, B | 1 |
| Brunstein, CG | 1 |
| Bachanova, V | 1 |
| Bruce, WR | 1 |
| Valeriote, FA | 1 |
| Meeker, BE | 1 |
| Hunter, A | 1 |
| Mahendra, P | 2 |
| Wilson, K | 1 |
| Fields, P | 1 |
| Cook, G | 1 |
| Crawley, C | 1 |
| Hickling, R | 1 |
| Marcus, R | 1 |
| Rzepecki, P | 1 |
| Pielichowski, W | 1 |
| Oborska, S | 1 |
| Barzal, J | 1 |
| Mlot, B | 1 |
| Bernstein, SH | 2 |
| Abboud, CN | 2 |
| Constine, LS | 1 |
| Ifthikharuddin, JJ | 2 |
| Loughner, JE | 1 |
| Vesole, DH | 2 |
| Lupov, IP | 1 |
| Voiles, L | 1 |
| Han, L | 1 |
| Schwartz, A | 1 |
| De La Rosa, M | 1 |
| Oza, K | 1 |
| Pelloso, D | 1 |
| Sahu, RP | 1 |
| Travers, JB | 1 |
| Robertson, MJ | 1 |
| Chang, HC | 1 |
| Lane, AA | 1 |
| Armand, P | 1 |
| Feng, Y | 1 |
| Neuberg, DS | 1 |
| Abramson, JS | 1 |
| Brown, JR | 1 |
| Fisher, DC | 1 |
| LaCasce, AS | 1 |
| Jacobsen, ED | 1 |
| McAfee, SL | 1 |
| Spitzer, TR | 1 |
| Freedman, AS | 1 |
| Chen, YB | 1 |
| Till, BG | 1 |
| Madtes, DK | 1 |
| Kasenda, B | 1 |
| Schorb, E | 1 |
| Fritsch, K | 1 |
| Illerhaus, G | 2 |
| O'Meara, A | 1 |
| Halter, J | 2 |
| Heim, D | 2 |
| Gerull, S | 1 |
| Bucher, C | 2 |
| Passweg, J | 1 |
| Buser, A | 1 |
| Stern, M | 2 |
| Shibamoto, Y | 1 |
| Tomita, N | 1 |
| Kono, T | 1 |
| Tsuji, H | 1 |
| Nankoh, S | 1 |
| Taniguchi, H | 1 |
| Au, WY | 1 |
| Lie, AK | 1 |
| Siu, LL | 1 |
| Chan, EC | 1 |
| Ooi, GC | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Poortmans, PM | 1 |
| Kluin-Nelemans, HC | 1 |
| Haaxma-Reiche, H | 1 |
| Van't Veer, M | 1 |
| Hansen, M | 1 |
| Soubeyran, P | 1 |
| Taphoorn, M | 1 |
| Thomas, J | 1 |
| Van den Bent, M | 1 |
| Fickers, M | 1 |
| Van Imhoff, G | 1 |
| Rozewicz, C | 1 |
| Teodorovic, I | 1 |
| van Glabbeke, M | 1 |
| Wang, EH | 1 |
| Chen, YA | 1 |
| Corringham, S | 1 |
| Bashey, A | 1 |
| Holman, P | 1 |
| Ball, ED | 1 |
| Carrier, E | 1 |
| Martín, A | 2 |
| Caballero, MD | 2 |
| Pérez-Simón, JA | 2 |
| López-Holgado, N | 2 |
| Mateos, MV | 1 |
| Cañizo, MC | 1 |
| Miguel, JF | 1 |
| Decaudin, D | 1 |
| Vantelon, JM | 1 |
| Bourhis, JH | 1 |
| Farace, F | 1 |
| Bonnet, ML | 1 |
| Guillier, M | 1 |
| Greissenger, N | 1 |
| Marracho, MC | 1 |
| Assari, S | 1 |
| Bennaceur, AL | 1 |
| Némati, F | 1 |
| Michon, J | 1 |
| Turhan, AG | 1 |
| Boccaccio, C | 1 |
| Korfel, A | 1 |
| Martus, P | 1 |
| Nowrousian, MR | 1 |
| Hossfeld, DK | 1 |
| Kirchen, H | 1 |
| Brücher, J | 1 |
| Stelljes, M | 1 |
| Peschel, C | 1 |
| Pasold, R | 1 |
| Fischer, L | 1 |
| Jahnke, K | 1 |
| Thiel, E | 2 |
| Vázquez, L | 1 |
| del Cañizo, MC | 1 |
| San Miguel, JF | 1 |
| Lancet, JE | 1 |
| Spreng, E | 1 |
| Johnson, V | 1 |
| Chapman, M | 1 |
| Steele, TA | 3 |
| Hauser, CC | 1 |
| Brevet, M | 1 |
| Garidi, R | 1 |
| Gruson, B | 1 |
| Royer, B | 1 |
| Vaida, I | 1 |
| Marks, R | 1 |
| Ihorst, G | 1 |
| Guttenberger, R | 1 |
| Ostertag, C | 1 |
| Derigs, G | 1 |
| Frickhofen, N | 1 |
| Feuerhake, F | 1 |
| Volk, B | 1 |
| Hölig, K | 1 |
| Platzbecker, U | 1 |
| Poppe-Thiede, K | 1 |
| Ordemann, R | 1 |
| Blechschmidt, M | 1 |
| Oelschlaegel, U | 1 |
| Schaich, M | 1 |
| Colombat, P | 1 |
| Lemevel, A | 1 |
| Bertrand, P | 1 |
| Rachieru, P | 1 |
| Brion, A | 1 |
| Berthou, C | 1 |
| Bay, JO | 1 |
| Delepine, R | 1 |
| Desablens, B | 1 |
| Camilleri-Broët, S | 1 |
| Linassier, C | 1 |
| Lamy, T | 1 |
| Buser, AS | 1 |
| Arber, C | 1 |
| Meyer-Monard, S | 1 |
| Stussi, G | 1 |
| Lohri, A | 1 |
| Ghielmini, M | 1 |
| Tichelli, A | 1 |
| Passweg, JR | 1 |
| Gratwohl, A | 1 |
| Horgan, CM | 1 |
| Tisdale, MJ | 1 |
| Portlock, CS | 1 |
| Maruyama, Y | 8 |
| Feola, JM | 4 |
| Muir, W | 1 |
| Oken, MM | 1 |
| Costello, WG | 1 |
| Johnson, GJ | 2 |
| Lenhard, RE | 4 |
| Ezdinli, EZ | 4 |
| Orlow, E | 1 |
| Barnes, JM | 2 |
| Berard, CW | 2 |
| Glick, JH | 3 |
| Tannir, NM | 1 |
| Spitzer, G | 1 |
| Zander, AR | 2 |
| Jagannath, S | 2 |
| Kanojia, M | 1 |
| Vellekoop, L | 1 |
| McLaughlin, P | 2 |
| Hagemeister, FJ | 1 |
| Dicke, KA | 1 |
| Philip, T | 1 |
| Biron, P | 1 |
| Hervé, P | 1 |
| Dutou, L | 1 |
| Ehrsam, A | 1 |
| Philip, I | 1 |
| Souillet, G | 1 |
| Plouvier, E | 1 |
| Le Mevel, A | 1 |
| Philippe, N | 1 |
| Marconi, P | 4 |
| Scaringi, L | 1 |
| Tissi, L | 3 |
| Puccetti, P | 3 |
| Cassone, A | 3 |
| Hartmann, O | 1 |
| Pein, F | 1 |
| Beaujean, F | 2 |
| Kalifa, C | 1 |
| Patte, C | 1 |
| Parmentier, C | 1 |
| Lemerle, J | 1 |
| Williams, AC | 1 |
| Guadagni, F | 1 |
| Roselli, M | 1 |
| Fuggetta, MP | 1 |
| Perno, CF | 1 |
| Goldin, A | 5 |
| Giuliani, A | 2 |
| Case, DC | 1 |
| Sklar, CA | 1 |
| Kim, TH | 1 |
| Ramsay, NK | 1 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Orlow, EL | 1 |
| Bennett, JM | 4 |
| Bistoni, F | 3 |
| Cenci, E | 2 |
| Pesce, CD | 1 |
| Biegel, JA | 3 |
| Boggs, SS | 3 |
| Conner, MK | 2 |
| Williams, A | 1 |
| Nava, C | 1 |
| Gibson, NW | 1 |
| Hickman, JA | 1 |
| Gomez, GA | 1 |
| Aggarwal, KK | 1 |
| Han, T | 1 |
| Schwartz, GN | 1 |
| Delfina Pesce, C | 1 |
| Boccanera, M | 1 |
| Feola, J | 2 |
| Nathan, CF | 1 |
| Cohn, ZA | 1 |
| Bartocci, A | 1 |
| Spreafico, F | 2 |
| Bonmassar, E | 3 |
| Stahel, RA | 1 |
| Jost, LM | 1 |
| Cerny, T | 1 |
| Pichert, G | 1 |
| Honegger, H | 1 |
| Tobler, A | 1 |
| Jacky, E | 1 |
| Fey, M | 1 |
| Platzer, E | 1 |
| Fuchsberger, P | 1 |
| Lakota, J | 1 |
| Castenskiold, EC | 1 |
| Kelsey, SM | 1 |
| Collins, PW | 1 |
| Coldwell, RD | 1 |
| Allen, PD | 1 |
| Side, LE | 1 |
| Makin, HL | 1 |
| Goldstone, AH | 5 |
| Newland, AC | 1 |
| Marquardt, P | 1 |
| Haferlach, T | 1 |
| Jacobs, S | 1 |
| Mülverstedt, T | 1 |
| Eckstein, V | 1 |
| Suttorp, M | 1 |
| Löffler, H | 1 |
| Müller-Ruchholtz, W | 1 |
| Schmitz, N | 2 |
| Klingemann, HG | 1 |
| Shepherd, JD | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Nantel, SH | 1 |
| Sutherland, HJ | 1 |
| Spinelli, JJ | 1 |
| Kalaycioglu, M | 1 |
| Kavuru, M | 1 |
| Tuason, L | 1 |
| Bolwell, B | 2 |
| Snyder, MJ | 1 |
| Johnson, DB | 1 |
| Daly, MB | 1 |
| Giguere, JK | 1 |
| Harman, GH | 1 |
| Harden, EA | 1 |
| Johnson, RA | 1 |
| Leff, RS | 1 |
| Mercier, RJ | 1 |
| Messerschmidt, GL | 1 |
| Demirer, T | 1 |
| Weaver, CH | 2 |
| Buckner, CD | 2 |
| Petersen, FB | 2 |
| Bensinger, WI | 1 |
| Sanders, J | 1 |
| Clift, RA | 1 |
| Lilleby, K | 1 |
| Anasetti, C | 2 |
| Martin, P | 2 |
| Adkins, DR | 1 |
| Salzman, D | 1 |
| Boldt, D | 1 |
| Kuhn, J | 1 |
| Irvin, R | 1 |
| Roodman, GD | 1 |
| Lyons, R | 1 |
| Smith, L | 1 |
| LeMaistre, CF | 1 |
| Barbot, C | 1 |
| Rice, A | 1 |
| Vanès, I | 1 |
| Mahon, FX | 1 |
| Jazwiec, B | 1 |
| Reiffers, J | 1 |
| Chatterjee, R | 1 |
| Mills, W | 2 |
| Katz, M | 1 |
| McGarrigle, HH | 1 |
| Attal, M | 1 |
| Canal, P | 1 |
| Schlaifer, D | 1 |
| Chatelut, E | 1 |
| Dezeuze, A | 1 |
| Huguet, F | 1 |
| Payen, C | 1 |
| Pris, J | 1 |
| Laurent, G | 1 |
| Appelbaum, FR | 2 |
| Clift, R | 1 |
| Singer, J | 1 |
| Press, O | 1 |
| Bensinger, W | 1 |
| Bianco, J | 1 |
| Crilley, P | 2 |
| Lazarus, H | 1 |
| Topolsky, D | 2 |
| Ciobanu, N | 2 |
| Creger, RJ | 2 |
| Fox, RM | 2 |
| Bulova, SI | 2 |
| Shina, DC | 2 |
| Gucalp, R | 2 |
| Cooper, BW | 2 |
| Patti, C | 1 |
| Majolino, I | 1 |
| Indovina, A | 1 |
| Vasta, S | 1 |
| Liberti, G | 1 |
| Gentile, S | 1 |
| Santoro, A | 1 |
| Pisa, R | 1 |
| Caronia, F | 1 |
| Carlson, K | 1 |
| Smedmyr, B | 1 |
| Hagberg, H | 1 |
| Oberg, G | 1 |
| Simonsson, B | 1 |
| Smith, RJ | 1 |
| Sweetenham, JW | 2 |
| Strang, J | 1 |
| Cox, DC | 2 |
| Rosenfeld, CS | 1 |
| LeFever, A | 1 |
| Taylor, R | 1 |
| List, A | 1 |
| Fay, J | 1 |
| Collins, R | 1 |
| Andrews, F | 1 |
| Pallansch, P | 1 |
| Schuster, MW | 1 |
| Resta, D | 1 |
| Levitt, D | 1 |
| Nemunaitis, J | 1 |
| Ager, S | 1 |
| Richards, EM | 1 |
| Bass, G | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Ossenkoppele, GJ | 2 |
| Schuurhuis, GJ | 1 |
| Jonkhoff, AR | 1 |
| Dräger, AM | 1 |
| Westra, G | 1 |
| Oberink, JW | 1 |
| Legdeur, MC | 1 |
| de Kreuk, AM | 1 |
| Zweegman, S | 1 |
| Huijgens, PC | 2 |
| Fielding, AK | 1 |
| Sullivan, AM | 1 |
| Watts, MJ | 1 |
| Jamieson, E | 1 |
| Knauf, WU | 1 |
| Koenigsmann, MP | 1 |
| Notter, M | 1 |
| Hoppe, B | 1 |
| Reufi, B | 1 |
| Oberberg, D | 1 |
| Berdel, WE | 1 |
| Diehl, V | 2 |
| Martínez, C | 2 |
| Martino, R | 3 |
| Cancelas, JA | 1 |
| Madoz, P | 2 |
| García, J | 1 |
| Brunet, S | 3 |
| Kröger, N | 1 |
| Zeller, W | 1 |
| Fehse, N | 1 |
| Hassan, HT | 1 |
| Krüger, W | 1 |
| Gutensohn, K | 1 |
| Lölliger, C | 1 |
| Przepiorka, D | 1 |
| van Besien, K | 1 |
| Khouri, I | 1 |
| Hagemeister, F | 1 |
| Samuels, B | 1 |
| Folloder, J | 1 |
| Ueno, NT | 1 |
| Molldrem, J | 1 |
| Mehra, R | 1 |
| Körbling, M | 2 |
| Giralt, S | 1 |
| Gajewski, J | 1 |
| Donato, M | 1 |
| Cleary, K | 1 |
| Claxton, D | 1 |
| Andersson, B | 1 |
| Anderlini, P | 1 |
| Champlin, R | 1 |
| Muñoz, L | 2 |
| Subirà, M | 1 |
| Sierra, J | 2 |
| Josting, A | 1 |
| Reiser, M | 1 |
| Wickramanayake, PD | 1 |
| Rueffer, U | 1 |
| Draube, A | 1 |
| Söhngen, D | 1 |
| Tesch, H | 1 |
| Wolf, J | 1 |
| Engert, A | 1 |
| Cull, GM | 1 |
| Haynes, AP | 1 |
| Byrne, JL | 1 |
| Carter, GI | 1 |
| Miflin, G | 1 |
| Rebello, P | 1 |
| Hale, G | 1 |
| Waldmann, H | 1 |
| Russell, NH | 1 |
| George, P | 1 |
| Wyre, RM | 1 |
| Bruty, SJ | 1 |
| Duncombe, AS | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Cabezudo, E | 1 |
| Santamaría, A | 1 |
| Perea, G | 1 |
| Briones, J | 1 |
| Salar, A | 1 |
| Slabý, J | 1 |
| Trnený, M | 1 |
| Procházka, B | 1 |
| Klener, P | 1 |
| Bessell, EM | 1 |
| López-Guillermo, A | 1 |
| Villá, S | 1 |
| Verger, E | 1 |
| Nomdedeu, B | 1 |
| Petit, J | 1 |
| Byrne, P | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Becherer, A | 1 |
| Mitterbauer, M | 1 |
| Jaeger, U | 1 |
| Kalhs, P | 1 |
| Greinix, HT | 1 |
| Karanikas, G | 1 |
| Pötzi, C | 1 |
| Raderer, M | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Bakemeier, RF | 1 |
| Carbone, PP | 2 |
| Ezdinli, E | 2 |
| Pocock, SJ | 2 |
| Durant, JR | 4 |
| Gams, RA | 2 |
| Bartolucci, AA | 3 |
| Dorfman, RF | 1 |
| Costello, W | 1 |
| Horton, J | 1 |
| Amorisi, EL | 1 |
| Stolbach, L | 1 |
| Wolter, J | 1 |
| Pitzurra, M | 1 |
| Frati, L | 1 |
| Drewinko, B | 2 |
| Loo, TL | 2 |
| Freireich, EJ | 1 |
| Norgard, MJ | 1 |
| Murad, TM | 1 |
| Langford, KH | 1 |
| Bonmassar, A | 1 |
| Smith, RH | 1 |
| Muren, O | 1 |
| Scott, RB | 1 |
| Frable, WJ | 1 |
| Costanzi, JJ | 1 |
| Raju, MR | 1 |
| Bains, E | 1 |
| Jett, J | 1 |
| Simon, R | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 2 |
| Loeb, V | 1 |
| Dorfman, R | 1 |
| Chan, YK | 1 |
| Houchens, DP | 1 |
| Fioretti, MC | 2 |
| Wollner, N | 2 |
| Burchenal, JH | 2 |
| Lieberman, PH | 2 |
| Exelby, PR | 1 |
| D'Angio, GJ | 1 |
| Murphy, ML | 2 |
| Exelby, P | 1 |
| D'Angio, G | 1 |
| Gottlieb, JA | 1 |
| Lazarus, HM | 1 |
| Smith, AG | 1 |
| Long, SG | 1 |
| Janmohammed, RM | 1 |
| Macdonald, DF | 1 |
| Leyland, MJ | 1 |
| Milligan, DW | 1 |
| Selvan, RS | 2 |
| Nagarkatti, PS | 3 |
| Nagarkatti, M | 4 |
| Turriziani, M | 1 |
| Bulgarini, B | 1 |
| De Vecchis, L | 1 |
| Ayash, LJ | 1 |
| Hunt, M | 1 |
| Antman, K | 1 |
| Nadler, L | 1 |
| Wheeler, C | 1 |
| Takvorian, T | 1 |
| Elias, A | 1 |
| Antin, JH | 1 |
| Greenough, T | 1 |
| Eder, JP | 1 |
| Sensi, M | 1 |
| Bergomi, M | 1 |
| Formelli, F | 1 |
| Parmiani, G | 1 |
| Boros, L | 1 |
| Peng, YM | 1 |
| Alberts, DS | 1 |
| Asbury, RF | 1 |
| Goodman, TL | 1 |
| Penn, TE | 1 |
| Hickox, DE | 1 |
| Ito, H | 1 |
| Rousseau, V | 1 |
| Goavec, M | 1 |
| Morizet, J | 1 |
| Stanislawski, M | 1 |
| Zackheim, HS | 1 |
| Epstein, EH | 1 |
| Crain, WR | 1 |
| Gingrich, RD | 1 |
| Ginder, GD | 1 |
| Burns, LJ | 1 |
| Wen, BC | 1 |
| Fyfe, MA | 1 |
| Fuschiotti, P | 1 |
| Dominici, P | 1 |
| Borri-Voltattorni, C | 1 |
| Romani, L | 1 |
| Keilholz, U | 1 |
| Fehrentz, D | 1 |
| Bauer, H | 1 |
| Hunstein, W | 1 |
| Kryscio, R | 1 |
| Cabanillas, F | 1 |
| Velasquez, WS | 1 |
| Hagemeister, FB | 1 |
| Redman, JR | 1 |
| Swan, F | 1 |
| Rodriguez, MA | 1 |
| Gaspard, MH | 1 |
| Maraninchi, D | 1 |
| Stoppa, AM | 1 |
| Gastaut, JA | 1 |
| Michel, G | 1 |
| Tubiana, N | 1 |
| Blaise, D | 1 |
| Novakovitch, G | 1 |
| Rossi, JF | 1 |
| Weiller, PJ | 1 |
| Malkin, MG | 1 |
| Shapiro, WR | 1 |
| Kaplan, AM | 2 |
| van der Lelie, J | 1 |
| Thomas, LL | 1 |
| Wijngaarden, MJ | 1 |
| Reijneke, RM | 1 |
| Anderson, CC | 1 |
| Souhami, RL | 1 |
| Harper, PG | 1 |
| McLennan, KA | 1 |
| Jones, M | 1 |
| Machin, SJ | 1 |
| Jelliffe, AM | 1 |
| Cawley, JC | 1 |
| Anderson, JR | 1 |
| Melvin, F | 1 |
| Davis, TE | 1 |
| O'Connell, MJ | 1 |
| Sullivan, MP | 1 |
| Boyett, J | 1 |
| Pullen, J | 1 |
| Crist, W | 1 |
| Doering, EJ | 1 |
| Trueworthy, R | 1 |
| Hvizdala, E | 1 |
| Ruymann, F | 1 |
| Steuber, CP | 1 |
| Rainey, M | 1 |
| Dandy, M | 1 |
| Silberman, H | 1 |
| Omura, G | 1 |
| Vonderheid, EC | 1 |
| Micaily, B | 1 |
| Cohen, IJ | 1 |
| Vogel, R | 1 |
| Matz, S | 1 |
| Weitz, R | 1 |
| Mor, C | 1 |
| Stern, S | 1 |
| Zaizov, R | 1 |
| Schabel, FM | 2 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Laster, WR | 1 |
| Cheeks, JB | 1 |
| Frei, E | 1 |
| De Vita, VT | 1 |
| Canellos, GP | 1 |
| Schein, PJ | 1 |
| Chabner, BA | 1 |
| Bagley, CM | 1 |
| Young, RC | 1 |
| Aungst, CW | 1 |
| Lessner, HE | 1 |
| Fairley, GH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)[NCT00003061] | Phase 2 | 50 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049] | Phase 2 | 78 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease[NCT00287248] | Phase 1 | 38 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Data Collection and Analysis of COVID-19 Patients Treated With ClorNovir® (Chlorpheniramine Maleate (0.4% Nasal Spray)[NCT05520944] | 1,000 participants (Anticipated) | Observational | 2021-08-26 | Active, not recruiting | |||
| Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors[NCT05349227] | 660 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders[NCT03415672] | Phase 2 | 133 participants (Actual) | Interventional | 2017-10-11 | Completed | ||
| Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis[NCT00001646] | Phase 3 | 10 participants | Interventional | 1997-08-31 | Completed | ||
| Building Strength Through Rehabilitation for Heart Failure Patients[NCT03615469] | 15 participants (Actual) | Interventional | 2018-09-06 | Terminated (stopped due to Low recruitment numbers) | |||
| Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health[NCT02562040] | 459 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor[NCT01652469] | Phase 3 | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Healthy Weight and Stress Management Study[NCT05279989] | 25 participants (Actual) | Interventional | 2021-12-01 | Completed | |||
| Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures[NCT01526265] | 2,185 participants (Anticipated) | Interventional | 2012-02-29 | Completed | |||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Comparison of Surgical Wound Healing and Complications Following Revision Hip and Knee Replacements, Utilising a 7-day Versus 14-day Negative Pressure Wound Therapy (NPWT) Dressing. A Randomised Controlled Trial.[NCT05389410] | 100 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | |||
| OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC[NCT03827577] | Phase 3 | 195 participants (Anticipated) | Interventional | 2019-10-01 | Recruiting | ||
| Phase II Study of Intensive Carmustine and Etoposide With Cisplatin or Cyclophosphamide, Followed By Rescue With Autologous Bone Marrow Treated In Vitro With Etoposide and/or Peripheral Blood Stem Cells Mobilized With Filgrastim (G-CSF) or Sargramostim (G[NCT00002461] | Phase 2 | 35 participants (Actual) | Interventional | 1988-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
The 6-min walk test (6MWT) estimates the person's ability to perform everyday activities by measuring the distance walked in a set time period. It will be used to measure exercise capacity, specific aim 2. Participants will be allowed use of an assistive device and will be instructed to move as quickly as they feel safe and comfortable over the 100-meter course for 6 minutes. As per the protocol, participants will be allowed to stop and rest if necessary. This test is recommended by the American Thoracic Society for patients with moderate to severe heart or lung disease. (NCT03615469)
Timeframe: From Baseline to 5-6 months
| Intervention | meters walked (Mean) |
|---|---|
| Neuromusclar Electrical Stimulation | 324 |
| Transcutaneous Electrical Stimulation | 250.6 |
Defined as time from the date of randomization until death from any cause. (NCT01652469)
Timeframe: All patients will be followed for survival status every 12 weeks up to 24 months after the last patient is randomized
| Intervention | months (Median) |
|---|---|
| A: Erlotinib | 7.1 |
| B: Docetaxel | 7.1 |
"Time from the date of randomization until documented progression or death without documented progression.~Assessment of Progressive Disease (PD) based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) Target lesions:At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.(Note: the appearance of one or more new lesions is also considered progression).~Non-target lesions:Unequivocal progression of existing non-target lesions. (Note:the appearance of one or more new lesions is also considered progression). To achieve 'unequivocal progression', there must be an overall level of substantial worsening in non-target disease such that,even in presence of SD or PR in target disease, the overall tumour burden has increased sufficiently" (NCT01652469)
Timeframe: The combined run in period, treatment and follow-up for PFS is expected to extend the study duration to a total of 24 months.
| Intervention | months (Median) |
|---|---|
| A: Erlotinib | 1.6 |
| B: Docetaxel | 3.0 |
Adverse events classified according to NCI CTCAE version 4 (NCT01652469)
Timeframe: Same as primary outcome: 24 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Experienced AE/SAE | No AE/SAE | Experienced SAE | |
| A: Erlotinib | 36 | 2 | 7 |
| B: Docetaxel | 39 | 2 | 19 |
11 reviews available for carmustine and Lymphoma
| Article | Year |
|---|---|
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 1994 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Treatment of cutaneous T-cell lymphoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Carmustine; Combined Modality Therapy; Humans; Immu | 1985 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosin | 1971 |
45 trials available for carmustine and Lymphoma
| Article | Year |
|---|---|
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Fr | 2020 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2022 |
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabin | 2019 |
LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Et | 2019 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hemat | 2016 |
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic St | 2016 |
BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Fem | 2017 |
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dou | 2009 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus | 2011 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival | 2013 |
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous | 2003 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; | 2004 |
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Culture Techniques; | 2004 |
Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 2004 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs | 2007 |
Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dru | 1981 |
Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug | 1982 |
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 1994 |
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Admi | 1996 |
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; | 1996 |
Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1997 |
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etopos | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Th | 2000 |
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central | 2002 |
Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
Topics: Bleomycin; Carmustine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug T | 1976 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Drug Evaluation; Drug | 1978 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow | 1992 |
BEAM autografting in lymphoma--experience at one centre.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1992 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1986 |
Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Stud | 1985 |
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Carmustine; Child; Child, Preschool; C | 1985 |
Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 1985 |
115 other studies available for carmustine and Lymphoma
| Article | Year |
|---|---|
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra | 2022 |
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; | 2023 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2023 |
The nutritional impact of CD19-targeted CAR-T therapy versus BEAM chemotherapy for adult patients with lymphoma.
Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Human | 2023 |
Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, P | 2020 |
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2020 |
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine | 2021 |
Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.
Topics: Bendamustine Hydrochloride; Cardiotoxicity; Carmustine; Hematopoietic Stem Cell Transplantation; Hum | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Ste | 2022 |
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmust | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; | 2018 |
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; F | 2018 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hemat | 2014 |
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hu | 2014 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyt | 2016 |
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; F | 2016 |
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoi | 2016 |
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 2016 |
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carmustine; | 2017 |
Survival of mice bearing a transplanted syngeneic lymphoma following treatment with cyclophosphamide, 5-fluorouracil, or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Fluor | 1967 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Huma | 2009 |
Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2011 |
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2012 |
BCNU-associated pneumonitis: portrait of a toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Etoposide; Female; Hum | 2012 |
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2012 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Gr | 2003 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplas | 2004 |
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bo | 2005 |
The role of interferon-alpha in a successful murine tumor therapy.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Prolifera | 2005 |
Antitumour imidazotetrazines--IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010, M & B 39565; NSC 353451).
Topics: Adenosine; Aminoimidazole Carboxamide; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carmus | 1984 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
1,3-bis(2-chloroethyl)-1-nitrosourea treatment of spontaneous radiogenic C57BL mouse leukemia/lymphoma.
Topics: Animals; Carmustine; Leukemia Virus, Murine; Leukemia, Radiation-Induced; Lymphoma; Lymphoma, Non-Ho | 1983 |
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1983 |
High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1983 |
Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin's malignant lymphoma with a very bad prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1983 |
Combined effects of chemotherapy and host antitumor response in a murine histocompatible lymphoma model.
Topics: Animals; Antineoplastic Agents; Candida albicans; Carmustine; Combined Modality Therapy; Fungal Vacc | 1984 |
High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 1984 |
Adoptive transfer of immunity by spleen cells from LSA-lymphoma mice cured by BCNU.
Topics: Animals; Bone Marrow; Carmustine; Immunization, Passive; Lymphoma; Mice; Mice, Inbred C57BL; Spleen; | 1984 |
Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
Topics: Animals; Carmustine; Dacarbazine; Gamma Rays; Histocompatibility Antigens; Immune Tolerance; Immunit | 1984 |
Comparison of M-2 protocol with COP in patients with nodular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cyclophos | 1984 |
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Carmustine; Child; Child, Preschoo | 1982 |
Immunopotentiation of anticancer chemotherapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Candida albicans; Carmustine; Cell Wall; Cry | 1982 |
In vivo sister chromatid exchange and cellular replication kinetics of normal and lymphoma AKR bone marrow cells.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Carmustine; Cell Cycle; Cell Line; Crossing Over, Genetic; | 1982 |
Cellular replication kinetics and persistence of sister chromatid exchange-inducing lesions in normal and lymphoma AKR cells following exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Bone Marrow; Bromodeoxyuridine; Carmustine; Cell Cycle; Cell Division; Cell Line; Crossing | 1982 |
Evidence for host resistance in 1,3 bis(2-chloroethyl)-1-nitrosourea treatment induced in syngeneic LSA lymphoma.
Topics: Animals; Carmustine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Female; Immunity, I | 1982 |
The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyanates; Female; Leukemia L1210; Lomustine; Lymphoma; M | 1982 |
A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Germanium; Karyotyping; Leukemia, Experiment | 1982 |
[Further study of immunopotentiation in experimental antiblastic therapy by inactivated yeasts and glucan].
Topics: Adjuvants, Immunologic; Animals; Carmustine; Combined Modality Therapy; Female; Fluorouracil; Glucan | 1982 |
1,3 Bis (2-chloroethyl)-1-nitrosourea-induced host resistance to syngeneic LSA mouse leukemia.
Topics: Animals; Carmustine; Hematopoietic Stem Cells; Immunity; Leukemia, Experimental; Lymphoma; Mice; Neo | 1980 |
Antitumor effects of hydrogen peroxide in vivo.
Topics: Animals; Antineoplastic Agents; Carmustine; Drug Synergism; Female; Glucose Oxidase; Hydrogen Peroxi | 1981 |
Combined effects of antineoplastic agents and anti-lymphoma allograft reactions.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Female; Histocompatibilit | 1980 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclo | 1995 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marr | 1995 |
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tra | 1993 |
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato | 1995 |
Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosph | 1994 |
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1993 |
High-dose cyclophosphamide, etoposide and BCNU (CVB) with autologous stem cell rescue in malignant lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colo | 1993 |
Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; | 1995 |
Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Cyclosporine; Imm | 1995 |
Elimination of EL-4 and L1210 murine tumors by 1,3-bis (2-chloroethyl)-1-nitrosourea requires an intact immune response.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cyclosporine; Immunosuppressive Agents; Leuk | 1996 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1996 |
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cold Temperature; | 1996 |
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide | 1996 |
Carmustine and the lungs .
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Female; Hodgkin Disease; Huma | 1997 |
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colon | 1998 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host | 1999 |
Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bact | 1999 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2000 |
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Automation; Biomarkers | 2000 |
Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Count; | 2000 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2002 |
Action of radiation or alkylating agents on LSA lymphoma during growth.
Topics: Alkylating Agents; Animals; Carmustine; Cell Survival; Cobalt Radioisotopes; Cyclophosphamide; Dose- | 1979 |
Host resistance to tumor after cure of advanced LSA lymphoma by treatment with BCNU and chlorozotocin.
Topics: Animals; Carmustine; Drug Therapy, Combination; Lymphoma; Male; Mice; Neoplasms, Experimental; Strep | 1979 |
Combined effects of BCG or Candida albicans (CA) with antitumor agents against a virus-induced lymphoma in mice.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; BCG Vaccine; Candida albicans; Carmustine; D | 1979 |
Combination chemotherapy in vitro. III. BCNU.
Topics: Antineoplastic Agents; Carmustine; Cell Survival; Drug Synergism; Humans; In Vitro Techniques; Lymph | 1979 |
Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).
Topics: Adolescent; Adult; Aged; Carmustine; Cough; Dyspnea; Female; Humans; Hypoxia; Lymphoma; Male; Middle | 1979 |
Influence of presensitization with allogeneic lymphoma cells on the growth and response to therapy of radiation-induced lymphomas in mice.
Topics: Animals; Carmustine; Female; Lymphoma; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental | 1979 |
Transbronchial brush biopsy: anti-mortem diagnosis of pulmonary infiltrates in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Bronchi; Bronchoscopy; Carmustine; Doxorubicin; Humans; Lung Neoplasms; Lymphoma; Male | 1978 |
Carmustine (BiCNU).
Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma | 1978 |
Study of in vivo tumor state and response to therapy by analysis of DNA distribution.
Topics: Animals; Carmustine; Cell Survival; Cobalt Radioisotopes; DNA, Neoplasm; Female; Hydroxyurea; Kineti | 1976 |
1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
Topics: Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Lar | 1975 |
Uptake of 5-iododeoxyuridine as a measure of tumor growth and tumor inhibition.
Topics: Animals; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; DNA, Neoplasm; Female; Idoxu | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami | 1976 |
A comparison of the lethal effects of three nitrosourea derivatives on cultured human lymphoma cells.
Topics: Amphotericin B; Carmustine; Cell Line; Cell Survival; Cells, Cultured; Dose-Response Relationship, D | 1976 |
Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice.
Topics: Animals; Carmustine; CD8 Antigens; Clone Cells; Cytotoxicity, Immunologic; Female; Interleukin-2; In | 1991 |
Role of levamisole as immunomodulant in mouse lymphoma model.
Topics: Animals; Carmustine; Cytarabine; Dacarbazine; Drug Synergism; Female; Immune Tolerance; Levamisole; | 1991 |
Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
Topics: Animals; Antibodies, Monoclonal; Antigen-Presenting Cells; Antigens, Differentiation, T-Lymphocyte; | 1990 |
Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas.
Topics: Adult; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Female; Hepatic Veno-Occl | 1990 |
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
Topics: Animals; Carmustine; Cytotoxicity, Immunologic; Female; Killer Cells, Lymphokine-Activated; Lymphoma | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biologi | 1990 |
Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Carmustine; Cell Survival; C | 1990 |
Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Carmustine; Drug Administration Schedule; | 1990 |
BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1990 |
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.
Topics: Animals; Azacitidine; Carmustine; Cell Line; Cytarabine; Dacarbazine; DNA, Neoplasm; Lymphoma; Male; | 1987 |
Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1989 |
Treatment of primary radiogenic C57BL mouse cell leukemia/lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy and adjuvant cellular therapy.
Topics: Animals; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Female; Immunotherapy; | 1985 |
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; | 1988 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1988 |
The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Topics: Animals; Carmustine; Cytotoxicity, Immunologic; Female; Graft Rejection; Immunity, Innate; Immunizat | 1985 |
Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Topics: Animals; Carmustine; Cell Line; Cytotoxicity, Immunologic; Female; Immunity, Cellular; Killer Cells, | 1988 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1988 |
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1986 |
Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine, and BCNU protocol (DEMOB).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child, Preschool; Dexam | 1986 |
Combination chemotherapy for spontaneous AKR lymphoma.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Development of four-drug BCNU combination chemotherapy regimens.
Topics: Carmustine; Cyclophosphamide; Evaluation Studies as Topic; Hematologic Diseases; Hodgkin Disease; Hu | 1973 |